A new study, Pharmacological OGG1 inhibition decreases murine allergic airway inflammation, was published 17[th] of October in Respiratory pharmacology, Frontiers in Pharmacology, (DOI 10.3389/fphar.2022.999180, Tanner L, Bergwik J, Bhongir RKV, Pan L, Dong C, Wallner O, Kalderén C, Helleday T, Boldogh I, Adner M and Egesten A) and demonstrates that Oxcia’s potential clinical candidate OXC-201 (TH5487) may be a promising treatment for allergic asthma.
Press releases
Enrolment completed and recommended phase II dose reached for OXC-101
Oxcia AB, today announced that it has completed enrollment and evaluation of the last patient in the MASTIFF Phase I clinical trial of OXC-101 in escalating doses for the treatment of patients with advanced solid malignant tumours. The recommended phase… Continue reading Enrolment completed and recommended phase II dose reached for OXC-101
Oxcia AB is strengthening the organization further
Several exciting pre-clinical and clinical studies are imminent. We are therefore happy that we have been able to recruit two very experienced and competent Scientists. Dr William Stafford has taken up the position as Translational Director from 1st of September.… Continue reading Oxcia AB is strengthening the organization further
New studies show OXC-101 further improves conventional chemotherapy treatment in Acute Myelom Leukemia (AML)
According to a new study published online 28 Feb 2022 (Centio et al., “Inhibition of oxidized nucleotide sanitation by TH1579 and conventional chemotherapy cooperatively enhance oxidative DNA-damage and survival in AML”, Mol Cancer Ther, doi: 10.1158/1535-7163.MCT-21-0185. Online ahead of print),… Continue reading New studies show OXC-101 further improves conventional chemotherapy treatment in Acute Myelom Leukemia (AML)
Oxcia reports positive interim data from clinical phase I study in advanced solid cancers
Oxcia reports positive interim data from the first part of the MASTIFF study, a phase 1 dose- escalation study with OXC-101 in patients with advanced solid cancers. Oxcia is a pioneer in oxidative DNA damage and DNA Damage Response (the… Continue reading Oxcia reports positive interim data from clinical phase I study in advanced solid cancers
Oxcia contracts Patheon for manufacturing and further strengthens the organization
Oxcia, a pioneer in oxidative DNA damage and DNA Damage Response (DDR) with a focus on developing new safe treatments for cancer and inflammation, has contracted Patheon for upscaling and production of OXC-101 substance and tablets for the upcoming Phase… Continue reading Oxcia contracts Patheon for manufacturing and further strengthens the organization